Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer's disease mice

Neta Lax1, Nina Fainstein1, Yossi Nishri1

  • 1Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.

Abstract

Insights

Systemic exposure to microbial Toll-like receptor 2 (TLR2) agonists accelerates neurodegeneration in Alzheimer's disease (AD) mouse models. This occurs via microglial activation within the AD brain, highlighting a potential mechanism for disease progression.

Area of Science:

  • Neuroscience
  • Immunology
  • Alzheimer's Disease Research

Background:

  • Microglia play a key role in cortical neuron death in Alzheimer's disease (AD).
  • Toll-like receptor 2 (TLR2) activation in microglia is implicated in neurotoxicity.
  • Amyloid deposition in preclinical AD correlates with microglial activation but not direct neurodegeneration.

Purpose of the Study:

  • To investigate if systemic Toll-like receptor 2 (TLR2) agonists accelerate neurodegeneration in AD.
  • To examine the role of microglia and TLR2 in mediating neurotoxicity in a transgenic AD mouse model (5xFAD).

Main Methods:

  • Administration of TLR2 agonists (zymosan, lipoteichoic acid) to wild-type and 5xFAD mice.
  • Evaluation of cortical neuron survival, microglial activation, and blood-brain barrier integrity.
  • Assessment of neurotoxicity through direct central nervous system (CNS) delivery of TLR2 agonists and antagonists.

Main Results:

  • Systemic TLR2 agonists caused cortical neuron death in 5xFAD mice but not wild-type mice.
  • TLR2 agonists crossed the disrupted blood-brain barrier in 5xFAD mice, with CNS TLR2 mediating the neurotoxicity.
  • 5xFAD mice showed increased vulnerability due to a higher number of neurotoxic, TLR2-expressing microglia.

Conclusions:

  • Repeated exposure to microbial TLR2 agonists may exacerbate neurodegeneration in AD.
  • Microglial-mediated toxicity, triggered by TLR2 agonists, contributes to neuronal loss in the AD brain environment.